Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially medi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Narasimhan, Narayana I, Dorer, David J, Niland, Katie, Haluska, Frank, Sonnichsen, Daryl
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2013
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781849/
https://ncbi.nlm.nih.gov/pubmed/23801357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.109
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky